APA (7th ed.) Citation

Aklillu, E., Zumla, A., Habtewold, A., Amogne, W., Makonnen, E., Yimer, G., . . . Diczfalusy, U. (2021). Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. British journal of pharmacology, 178(16), . https://doi.org/10.1111/bph.15309

Chicago Style (17th ed.) Citation

Aklillu, Eleni, Alimuddin Zumla, Abiy Habtewold, Wondwossen Amogne, Eyasu Makonnen, Getnet Yimer, Jürgen Burhenne, and Ulf Diczfalusy. "Early or Deferred Initiation of Efavirenz During Rifampicin-based TB Therapy Has No Significant Effect on CYP3A Induction in TB-HIV Infected Patients." British Journal of Pharmacology 178, no. 16 (2021). https://doi.org/10.1111/bph.15309.

MLA (9th ed.) Citation

Aklillu, Eleni, et al. "Early or Deferred Initiation of Efavirenz During Rifampicin-based TB Therapy Has No Significant Effect on CYP3A Induction in TB-HIV Infected Patients." British Journal of Pharmacology, vol. 178, no. 16, 2021, https://doi.org/10.1111/bph.15309.